InSCREENeX

Executive Summary

InSCREENeX GmbH is a German biotechnology company that provides custom cell line generation and immortalization services for pharmaceutical and research applications. Founded in 2015 by scientists from the Helmholtz Centre for Infection Research in Braunschweig, the company leverages proprietary technologies to create stable, functional cell lines that accelerate drug discovery and development. Its offerings include stable cell line generation, cell immortalization, and cell-based assay development, serving biopharma and academic clients. By focusing on high-quality, reproducible cell models, InSCREENeX addresses a critical bottleneck in preclinical research. The company operates as a service provider in the contract research organization (CRO) space, with a niche in immortalization technology. While private and without disclosed funding, its expertise positions it as a potential partner for large pharma and biotech firms seeking reliable cell lines for screening and target validation.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with major pharmaceutical company40% success
• Q4 2026Launch of new cell line platform leveraging AI/ML for predictive biology30% success
• Q2 2026Receipt of grant or funding from European innovation programs for cell line development50% success